LOGIN  |  REGISTER

Zoetis Announces Third Quarter 2023 Results

November 02, 2023 | Last Trade: US$164.80 1.28 0.78
  • Reports Revenue of $2.2 Billion, Growing 7%, and Net Income of $596 Million, or $1.29 per Diluted Share, Increasing 13% and 14%, Respectively, on a Reported Basis for Third Quarter 2023
  • Delivers 8% Operational Growth in Revenue and a 13% Operational Growth in Adjusted Net Income for Third Quarter 2023
  • Reports Adjusted Net Income of $629 Million, or Adjusted Diluted EPS of $1.36, for Third Quarter 2023
  • Updates Full Year 2023 Revenue Guidance Range of $8.475 - $8.550 Billion Due to the Impact of Foreign Exchange Rates
  • Narrows Full Year 2023 Guidance for Operational Revenue Growth to a Range of 6.5% to 7.5% and Adjusted Net Income of 7.5% to 8.5%

PARSIPPANY, N.J. / Nov 02, 2023 / Business Wire / Zoetis Inc. (NYSE: ZTS) today reported its financial results for the third quarter of 2023 and updated its guidance for full year 2023.

The company reported revenue of $2.2 billion for the third quarter of 2023, an increase of 7% compared with the third quarter of 2022. On an operational1 basis, revenue for the third quarter of 2023 increased 8% compared with the third quarter of 2022, excluding the impact of foreign currency. Net income for the third quarter of 2023 was $596 million, or $1.29 per diluted share, an increase of 13% and 14%, respectively, on a reported basis.

Adjusted net income2 for the third quarter of 2023 was $629 million, or $1.36 per diluted share, an increase of 11% and 12%, respectively, on a reported basis, and an increase of 13% and 15%, respectively, on an operational basis. Adjusted net income for the third quarter of 2023 excludes the net impact of $33 million for purchase accounting adjustments, acquisition-related costs and certain significant items.

EXECUTIVE COMMENTARY

“Today we reported strong third quarter results of 8% operational growth in revenue and 13% operational growth in adjusted net income, based on our diverse portfolio across markets and species," said Kristin Peck, Chief Executive Officer of Zoetis. “We showed balanced segment growth again this quarter, with 8% revenue growth in the U.S. and 8% operational revenue growth internationally. Our companion animal portfolio grew 11% operationally, driven by our major franchises in dermatology, pet parasiticides, osteoarthritis pain and diagnostics. Our livestock portfolio grew 3% operationally, driven by sales of poultry and cattle products.”

“We are on track to achieve our full-year operational guidance and have narrowed it around the mid-point of the range. We remain confident in the sustainable, underlying demand for animal health, as customers continue to place a premium on the animal health benefits our products deliver. We are executing well on drivers where we have more control, like the successful launch of Librela® in the U.S., while also mitigating the downside of macroeconomic declines in China. Once again, our diverse portfolio across product categories and geographies provides us with durable, reliable, long-term growth.”

QUARTERLY HIGHLIGHTS

Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the third quarter of 2023:

  • Revenue in the U.S. segment was $1.174 billion, an increase of 8% compared with the third quarter of 2022. Sales of companion animal products increased 11%, driven by the company’s key dermatology portfolio, including Apoquel® and Cytopoint®, as well as the company's parasiticide product Simparica Trio®. Also contributing to growth in the quarter was Solensia®, a monoclonal antibody for osteoarthritis pain in cats, and the company's diagnostics portfolio of Vetscan® products. Sales of livestock products declined 2% in the quarter. Sales of cattle products decreased primarily due to a difficult comparable period versus the same quarter last year. Sales of swine products declined in the quarter, as a result of lower disease prevalence and unfavorable market conditions. Declines in cattle and swine were partially offset by growth in the poultry portfolio due to vaccines and the expanded use of Zoamix®, an alternative to antibiotic medicated feed additives (MFAs).
  • Revenue in the International segment was $956 million, reflecting an increase of 8% on both a reported and operational basis, compared with the third quarter of 2022. Sales of companion animal products grew 12% on both a reported and operational basis, despite declines in China. Growth in the quarter was driven by the company’s monoclonal antibody products for osteoarthritis pain, Librela for dogs and Solensia for cats, as well as its key dermatology products, Apoquel and Cytopoint. Also contributing to growth in the quarter were Simparica® and Simparica Trio. Sales of livestock products grew 3% on a reported basis and 5% operationally. Growth in cattle was driven largely by price, improved supply and channel dynamics as well as strong market conditions in Brazil. Sales of poultry products experienced price increases across the international segment and MFAs grew in key regions. Sales in swine grew primarily from demand generation efforts in key and emerging markets. 

INVESTMENTS IN GROWTH

Zoetis continues to grow key product franchises through additional claim extensions in major markets. In the third quarter, Simparica Trio (sarolaner/moxidectin/pyrantel), the company’s triple combination oral parasiticide for dogs, received approval in Australia and Canada for claims related to efficacy against sarcoptic and demodectic manges. Simparica Trio also received approval for two additional claims in Australia – Otodectes cynotis and flea tapeworms. Additionally, Simparica (sarolaner) received approval in Canada for claims related to Otodectes cynotis mange.

Zoetis also continues to advance pain management and dermatology innovation for companion animals across the globe. With the October launch of Librela (bedinvetmab injection) and Apoquel Chewable (oclacitinib chewable tablet) in the U.S., three of the company’s major franchises – including Solensia (frunevetmab injection) – are now available in most major markets around the world, with ongoing geographic expansion continuing in additional markets.

FINANCIAL GUIDANCE

Zoetis is updating its full year reported 2023 guidance due to foreign exchange rates.

  • Updates revenue to between $8.475 billion to $8.550 billion (narrows operational growth to a range of 6.5% to 7.5%)
  • Updates reported net income to between $2.380 billion to $2.415 billion
  • Updates adjusted net income to between $2.490 billion to $2.515 billion (narrows operational growth to a range of 7.5% to 8.5%)
  • Updates reported diluted EPS of $5.14 to $5.21 due to the impact of foreign exchange rates
  • Updates adjusted diluted EPS between $5.38 to $5.43 due to the impact of foreign exchange rates

This guidance reflects foreign exchange rates as of late October. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS

Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review third quarter 2023 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on November 2, 2023.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

1 Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.

2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZOETIS INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)

(UNAUDITED)

(millions of dollars, except per share data)

        

 

Three Months Ended

 

 

 

Nine Months Ended

 

 

September 30,

 

 

 

September 30,

 

 

 

2023

 

 

2022

 

% Change

 

 

2023

 

 

2022

 

% Change

Revenue

$

2,151

 

$

2,002

 

7

 

$

6,331

 

$

6,040

 

5

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

638

 

 

607

 

5

 

 

1,833

 

 

1,801

 

2

Selling, general and administrative expenses

 

525

 

 

501

 

5

 

 

1,586

 

 

1,495

 

6

Research and development expenses

 

152

 

 

134

 

13

 

 

440

 

 

391

 

13

Amortization of intangible assets

 

38

 

 

37

 

3

 

 

112

 

 

115

 

(3)

Restructuring charges and certain acquisition-related costs

 

16

 

 

6

 

*

 

 

45

 

 

9

 

*

Interest expense, net of capitalized interest

 

59

 

 

53

 

11

 

 

180

 

 

159

 

13

Other (income)/deductions–net

 

6

 

 

(3)

 

*

 

 

(151)

 

 

6

 

*

Income before provision for taxes on income

 

717

 

 

667

 

7

 

 

2,286

 

 

2,064

 

11

Provision for taxes on income

 

121

 

 

139

 

(13)

 

 

469

 

 

413

 

14

Net income before allocation to noncontrolling interests

 

596

 

 

528

 

13

 

 

1,817

 

 

1,651

 

10

Less: Net loss attributable to noncontrolling interests

 

 

 

(1)

 

*

 

 

(2)

 

 

(2)

 

Net income attributable to Zoetis Inc.

$

596

 

$

529

 

13

 

$

1,819

 

$

1,653

 

10

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share—basic

$

1.29

 

$

1.13

 

14

 

$

3.94

 

$

3.52

 

12

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share—diluted

$

1.29

 

$

1.13

 

14

 

$

3.93

 

$

3.51

 

12

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares used to calculate earnings per share

 

 

 

 

 

 

 

 

 

 

 

Basic

 

460.3

 

 

467.8

 

 

 

 

461.9

 

 

470.0

 

 

Diluted

 

461.4

 

 

469.1

 

 

 

 

463.0

 

 

471.6

 

 

(a) The condensed consolidated statements of income present the three and nine months ended September 30, 2023 and 2022. Subsidiaries operating outside the United States are included for the three and nine months ended August 31, 2023 and 2022.

* Calculation not meaningful.

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

 

   

 

 

Three months ended September 30, 2023

 

 

GAAP Reported(a)

 

Purchase Accounting Adjustments

 

Acquisition- Related Costs(1)

 

Certain Significant Items(2)

 

Non-GAAP Adjusted(b)

Cost of sales

 

$

638

 

$

(1)

 

$

 

$

(2)

 

$

635

Gross profit

 

 

1,513

 

 

1

 

 

 

 

2

 

 

1,516

Selling, general and administrative expenses

 

 

525

 

 

(4)

 

 

 

 

 

 

521

Research and development expenses

 

 

152

 

 

(1)

 

 

 

 

 

 

151

Amortization of intangible assets

 

 

38

 

 

(33)

 

 

 

 

 

 

5

Restructuring charges and certain acquisition-related costs

 

 

16

 

 

 

 

(3)

 

 

(13)

 

 

Other (income)/deductions–net

 

 

6

 

 

 

 

 

 

(8)

 

 

(2)

Income before provision for taxes on income

 

 

717

 

 

39

 

 

3

 

 

23

 

 

782

Provision for taxes on income

 

 

121

 

 

9

 

 

 

 

23

 

 

153

Net income attributable to Zoetis

 

 

596

 

 

30

 

 

3

 

 

 

 

629

Earnings per common share attributable to Zoetis–diluted

 

 

1.29

 

 

0.06

 

 

0.01

 

 

 

 

1.36

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30, 2022

 

 

GAAP Reported(a)

 

Purchase Accounting Adjustments

 

Acquisition- Related Costs(1)

 

Certain Significant Items(2)

 

Non-GAAP Adjusted(b)

Cost of sales

 

$

607

 

$

(1)

 

$

 

$

(1)

 

$

605

Gross profit

 

 

1,395

 

 

1

 

 

 

 

1

 

 

1,397

Selling, general and administrative expenses

 

 

501

 

 

(8)

 

 

 

 

 

 

493

Amortization of intangible assets

 

 

37

 

 

(31)

 

 

 

 

 

 

6

Restructuring charges and certain acquisition-related costs

 

 

6

 

 

 

 

(1)

 

 

(5)

 

 

Income before provision for taxes on income

 

 

667

 

 

40

 

 

1

 

 

6

 

 

714

Provision for taxes on income

 

 

139

 

 

9

 

 

 

 

1

 

 

149

Net income attributable to Zoetis

 

 

529

 

 

31

 

 

1

 

 

5

 

 

566

Earnings per common share attributable to Zoetis–diluted

 

 

1.13

 

 

0.07

 

 

 

 

0.01

 

 

1.21

(a) The condensed consolidated statements of income present the three months ended September 30, 2023 and 2022. Subsidiaries operating outside the United States are included for the three months ended August 31, 2023 and 2022.

(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

 

   

 

 

Nine Months Ended September 30, 2023

 

 

GAAP Reported(a)

 

Purchase Accounting Adjustments

 

Acquisition- Related Costs(1)

 

Certain Significant Items(2)

 

Non-GAAP Adjusted(b)

Cost of sales

 

$

1,833

 

$

(10)

 

$

 

$

(2)

 

$

1,821

Gross profit

 

 

4,498

 

 

10

 

 

 

 

2

 

 

4,510

Selling, general and administrative expenses

 

 

1,586

 

 

(18)

 

 

 

 

 

 

1,568

Research and development expenses

 

 

440

 

 

(1)

 

 

 

 

 

 

439

Amortization of intangible assets

 

 

112

 

 

(95)

 

 

 

 

 

 

17

Restructuring charges and certain acquisition-related costs

 

 

45

 

 

 

 

(8)

 

 

(37)

 

 

Other (income)/deductions–net

 

 

(151)

 

 

 

 

 

 

84

 

 

(67)

Income before provision for taxes on income

 

 

2,286

 

 

124

 

 

8

 

 

(45)

 

 

2,373

Provision for taxes on income

 

 

469

 

 

26

 

 

1

 

 

(9)

 

 

487

Net income attributable to Zoetis

 

 

1,819

 

 

98

 

 

7

 

 

(36)

 

 

1,888

Earnings per common share attributable to Zoetis–diluted

 

 

3.93

 

 

0.21

 

 

0.02

 

 

(0.08)

 

 

4.08

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2022

 

 

GAAP Reported(a)

 

Purchase Accounting Adjustments

 

Acquisition- Related Costs(1)

 

Certain Significant Items(2)

 

Non-GAAP Adjusted(b)

Cost of sales

 

$

1,801

 

$

(3)

 

$

 

$

(8)

 

$

1,790

Gross profit

 

 

4,239

 

 

3

 

 

 

 

8

 

 

4,250

Selling, general and administrative expenses

 

 

1,495

 

 

(22)

 

 

 

 

 

 

1,473

Amortization of intangible assets

 

 

115

 

 

(95)

 

 

 

 

 

 

20

Restructuring charges and certain acquisition-related costs

 

 

9

 

 

 

 

(4)

 

 

(5)

 

 

Other (income)/deductions–net

 

 

6

 

 

 

 

 

 

3

 

 

9

Income before provision for taxes on income

 

 

2,064

 

 

120

 

 

4

 

 

10

 

 

2,198

Provision for taxes on income

 

 

413

 

 

28

 

 

1

 

 

 

 

442

Net income attributable to Zoetis

 

 

1,653

 

 

92

 

 

3

 

 

10

 

 

1,758

Earnings per common share attributable to Zoetis–diluted

 

 

3.51

 

 

0.20

 

 

 

 

0.02

 

 

3.73

(a) The condensed consolidated statements of income present the nine months ended September 30, 2023 and 2022. Subsidiaries operating outside the United States are included for the nine months ended August 31, 2023 and 2022.

(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)

 

 

(1) Acquisition-related costs include the following:

    

 

Three Months Ended

 

Nine Months Ended

 

September 30,

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

Integration costs(a)

$

1

 

$

1

 

$

3

 

$

4

Transaction costs(b)

 

2

 

 

 

 

4

 

 

Restructuring charges(c)

 

 

 

 

 

1

 

 

Total acquisition-related costs—pre-tax

 

3

 

 

1

 

 

8

 

 

4

Income taxes(d)

 

 

 

 

 

1

 

 

1

Total acquisition-related costs—net of tax

$

3

 

$

1

 

$

7

 

$

3

(a) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes. Included in Restructuring charges and certain acquisition-related costs.

(b) Transaction costs represent external costs directly related to acquiring businesses and primarily includes expenditures for banking, legal, accounting and other similar services. Included in Restructuring charges and certain acquisition-related costs.

(c) Represents employee termination costs, included in Restructuring charges and certain acquisition-related costs.

(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

(2) Certain significant items include the following:

   

 

Three Months Ended

 

Nine Months Ended

 

September 30,

 

September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

Other restructuring charges and cost-reduction/productivity initiatives(a)

$

12

 

$

4

 

$

36

 

$

7

Certain asset impairment charges(b)

 

11

 

 

2

 

 

21

 

 

6

Net gain on sale of business(c)

 

 

 

 

 

(101)

 

 

Other

 

 

 

 

 

(1)

 

 

(3)

Total certain significant items—pre-tax

 

23

 

 

6

 

 

(45)

 

 

10

Income taxes(d)

 

23

 

 

1

 

 

(9)

 

 

Total certain significant items—net of tax

$

 

$

5

 

$

(36)

 

$

10

(a) For the three and nine months ended September 30, 2023, primarily consisted of employee termination and exit costs related to organizational structure refinements and other cost-reduction and productivity initiatives, included in Restructuring charges and certain acquisition-related costs.

For the three and nine months ended September 30, 2022, primarily represents employee termination and exit costs associated with cost-reduction and productivity initiatives in certain international markets, included in Restructuring charges and certain acquisition-related costs, as well as product transfer costs, included in Cost of sales.

(b) For the three and nine months ended September 30, 2023, represents certain asset impairment charges related to our precision animal health and diagnostics businesses, primarily included in Other (income)/deductions–net.

For the three and nine months ended September 30, 2022, represents inventory and certain asset impairment charges primarily related to the consolidation of manufacturing sites in China, included in Cost of sales and Restructuring charges and certain acquisition-related costs, respectively.

(c) Primarily represents a net gain on the sale of a majority interest in our pet insurance business, included in Other (income)/deductions–net.

(d) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. Income taxes in Certain significant items also includes:

  • For the three and nine months ended September 30, 2023, a benefit from the tax loss on the divestiture of Performance Livestock Analytics, partially offset by a tax expense related to changes to prior years' tax positions with regard to the one-time mandatory deemed repatriation tax under the Tax Cuts and Jobs Act.
  • For the nine months ended September 30, 2022, changes in valuation allowances.

 

ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)
(UNAUDITED)
(millions of dollars)

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

Adjusted cost of sales

 

$

635

 

$

605

 

5 %

 

 

— %

 

5 %

as a percent of revenue

 

 

29.5 %

 

 

30.2 %

 

NA

 

 

NA

 

NA

Adjusted SG&A expenses

 

 

521

 

 

493

 

6 %

 

 

1 %

 

5 %

Adjusted R&D expenses

 

 

151

 

 

134

 

13 %

 

 

— %

 

13 %

Adjusted net income attributable to Zoetis

 

 

629

 

 

566

 

11 %

 

 

(2) %

 

13 %

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

Adjusted cost of sales

 

$

1,821

 

$

1,790

 

2 %

 

 

(6) %

 

8 %

as a percent of revenue

 

 

28.8 %

 

 

29.6 %

 

NA

 

 

NA

 

NA

Adjusted SG&A expenses

 

 

1,568

 

 

1,473

 

6 %

 

 

(2) %

 

8 %

Adjusted R&D expenses

 

 

439

 

 

391

 

12 %

 

 

(1) %

 

13 %

Adjusted net income attributable to Zoetis

 

 

1,888

 

 

1,758

 

7 %

 

 

— %

 

7 %

(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.

(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.

ZOETIS INC.

2023 GUIDANCE

Selected Line Items

(millions of dollars, except per share amounts)

Full Year 2023

Revenue

$8,475 to $8,550

Operational growth(a)

6.5% to 7.5%

Adjusted cost of sales as a percentage of revenue(b)

Approximately 29%

Adjusted SG&A expenses(b)

$2,095 to $2,115

Adjusted R&D expenses(b)

$600 to $610

Adjusted interest expense and other (income)/deductions-net(b)

Approximately $160

Effective tax rate on adjusted income(b)

20.0% to 20.5%

Adjusted diluted EPS(b)

$5.38 to $5.43

Adjusted net income(b)

$2,490 to $2,515

Operational growth(a)(c)

7.5% to 8.5%

Certain significant items and acquisition-related costs(d)

$(15) - $(25)

The guidance reflects foreign exchange rates as of late October 2023.

 

Reconciliations of 2023 reported guidance to 2023 adjusted guidance follows:

(millions of dollars, except per share amounts)

Reported

Certain significant items and acquisition-related costs(d)

Purchase accounting

Adjusted(c)

Cost of sales as a percentage of revenue

~ 29.2%

 

~ (0.2%)

~ 29.0%

SG&A expenses

$2,125 to $2,145

 

~ $(30)

$2,095 to $2,115

R&D expenses

$601 to $611

 

~ $(1)

$600 to $610

Interest expense and other (income)/deductions-net

~ $70

~ $90

 

~ $160

Effective tax rate

20.0% to 20.5%

 

 

20.0% to 20.5%

Diluted EPS

$5.14 to $5.21

$(0.03) - $(0.05)

~ $0.27

$5.38 to $5.43

Net income attributable to Zoetis

$2,380 to $2,415

$(15) - $(25)

~ $125

$2,490 to $2,515

(a) Operational growth (a non-GAAP financial measure) excludes the impact of foreign exchange.

(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational growth to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

(d) Primarily includes certain nonrecurring costs related to acquisitions and other charges.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

 

 

 

Three Months Ended

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

1,414

 

$

1,271

 

11 %

 

 

— %

 

11 %

Livestock

 

 

716

 

 

708

 

1 %

 

 

(2) %

 

3 %

Contract Manufacturing & Human Health

 

 

21

 

 

23

 

(9) %

 

 

3 %

 

(12) %

Total Revenue

 

$

2,151

 

$

2,002

 

7 %

 

 

(1) %

 

8 %

 

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

908

 

$

819

 

11 %

 

 

— %

 

11 %

Livestock

 

 

266

 

 

271

 

(2) %

 

 

— %

 

(2) %

Total U.S. Revenue

 

$

1,174

 

$

1,090

 

8 %

 

 

— %

 

8 %

 

 

 

 

 

 

 

 

 

 

 

 

International

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

506

 

$

452

 

12 %

 

 

— %

 

12 %

Livestock

 

 

450

 

 

437

 

3 %

 

 

(2) %

 

5 %

Total International Revenue

 

$

956

 

$

889

 

8 %

 

 

— %

 

8 %

 

 

 

 

 

 

 

 

 

 

 

 

Companion Animal:

 

 

 

 

 

 

 

 

 

 

 

Dogs and Cats

 

$

1,354

 

$

1,213

 

12 %

 

 

1 %

 

11 %

Horses

 

 

60

 

 

58

 

3 %

 

 

1 %

 

2 %

Total Companion Animal Revenue

 

$

1,414

 

$

1,271

 

11 %

 

 

— %

 

11 %

 

 

 

 

 

 

 

 

 

 

 

 

Livestock:

 

 

 

 

 

 

 

 

 

 

 

Cattle

 

$

374

 

$

371

 

1 %

 

 

(1) %

 

2 %

Swine

 

 

129

 

 

129

 

— %

 

 

(1) %

 

1 %

Poultry

 

 

127

 

 

116

 

9 %

 

 

(2) %

 

11 %

Fish

 

 

57

 

 

60

 

(5) %

 

 

(3) %

 

(2) %

Sheep and other

 

 

29

 

 

32

 

(9) %

 

 

(3) %

 

(6) %

Total Livestock Revenue

 

$

716

 

$

708

 

1 %

 

 

(2) %

 

3 %

 

 

 

 

 

 

 

 

 

 

 

 

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.
(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

 

 

 

Nine Months Ended

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

4,128

 

$

3,900

 

6 %

 

 

(1) %

 

7 %

Livestock

 

 

2,145

 

 

2,081

 

3 %

 

 

(3) %

 

6 %

Contract Manufacturing & Human Health

 

 

58

 

 

59

 

(2) %

 

 

— %

 

(2) %

Total Revenue

 

$

6,331

 

$

6,040

 

5 %

 

 

(2) %

 

7 %

 

 

 

 

 

 

 

 

 

 

 

 

U.S.

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

2,588

 

$

2,488

 

4 %

 

 

— %

 

4 %

Livestock

 

 

756

 

 

713

 

6 %

 

 

— %

 

6 %

Total U.S. Revenue

 

$

3,344

 

$

3,201

 

4 %

 

 

— %

 

4 %

 

 

 

 

 

 

 

 

 

 

 

 

International

 

 

 

 

 

 

 

 

 

 

 

Companion Animal

 

$

1,540

 

$

1,412

 

9 %

 

 

(4) %

 

13 %

Livestock

 

 

1,389

 

 

1,368

 

2 %

 

 

(4) %

 

6 %

Total International Revenue

 

$

2,929

 

$

2,780

 

5 %

 

 

(5) %

 

10 %

 

 

 

 

 

 

 

 

 

 

 

 

Companion Animal:

 

 

 

 

 

 

 

 

 

 

 

Dogs and Cats

 

$

3,931

 

$

3,715

 

6 %

 

 

(1) %

 

7 %

Horses

 

 

197

 

 

185

 

6 %

 

 

(2) %

 

8 %

Total Companion Animal Revenue

 

$

4,128

 

$

3,900

 

6 %

 

 

(1) %

 

7 %

 

 

 

 

 

 

 

 

 

 

 

 

Livestock:

 

 

 

 

 

 

 

 

 

 

 

Cattle

 

$

1,102

 

$

1,063

 

4 %

 

 

(2) %

 

6 %

Swine

 

 

404

 

 

427

 

(5) %

 

 

(3) %

 

(2) %

Poultry

 

 

397

 

 

361

 

10 %

 

 

(3) %

 

13 %

Fish

 

 

158

 

 

151

 

5 %

 

 

(4) %

 

9 %

Sheep and other

 

 

84

 

 

79

 

6 %

 

 

(7) %

 

13 %

Total Livestock Revenue

 

$

2,145

 

$

2,081

 

3 %

 

 

(3) %

 

6 %

 

 

 

 

 

 

 

 

 

 

 

 

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

 

ZOETIS INC.

CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS

(UNAUDITED)

(millions of dollars)

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

September 30,

 

% Change

 

 

2023

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(a)

Total International

 

$ 956.2

 

$ 888.8

 

8 %

 

 

— %

 

8 %

Australia

 

84.2

 

79.5

 

6 %

 

 

(5) %

 

11 %

Brazil

 

100.0

 

70.6

 

42 %

 

 

8 %

 

34 %

Canada

 

63.9

 

56.5

 

13 %

 

 

(3) %

 

16 %

Chile

 

30.5

 

30.9

 

(1) %

 

 

2 %

 

(3) %

China

 

69.0

 

92.1

 

(25) %

 

 

(5) %

 

(20) %

France

 

34.3

 

27.8

 

23 %

 

 

5 %

 

18 %

Germany

 

50.5

 

43.3

 

17 %

 

 

7 %

 

10 %

Italy

 

25.8

 

23.6

 

9 %

 

 

7 %

 

2 %

Japan

 

34.1

 

37.0

 

(8) %

 

 

(5) %

 

(3) %

Mexico

 

42.2

 

32.6

 

29 %

 

 

20 %

 

9 %

Spain

 

30.5

 

28.6

 

7 %

 

 

7 %

 

— %

United Kingdom

 

77.6

 

59.7

 

30 %

 

 

6 %

 

24 %

Other developed markets

 

127.1

 

120.5

 

5 %

 

 

1 %

 

4 %

Other emerging markets

 

186.5

 

186.1

 

— %

 

 

(12) %

 

12 %

 

 

Nine Months Ended

 

 

 

 

 

 

 

 

 

September 30,

 

% Change

 

 

2023

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(a)

Total International

 

$ 2,929.1

 

$ 2,779.5

 

5 %

 

 

(5) %

 

10 %

Australia

 

247.7

 

224.5

 

10 %

 

 

(7) %

 

17 %

Brazil

 

275.5

 

233.3

 

18 %

 

 

3 %

 

15 %

Canada

 

183.5

 

172.3

 

7 %

 

 

(5) %

 

12 %

Chile

 

108.8

 

106.3

 

2 %

 

 

1 %

 

1 %

China

 

255.3

 

291.0

 

(12) %

 

 

(6) %

 

(6) %

France

 

101.9

 

91.0

 

12 %

 

 

— %

 

12 %

Germany

 

148.3

 

132.3

 

12 %

 

 

— %

 

12 %

Italy

 

86.9

 

85.6

 

2 %

 

 

1 %

 

1 %

Japan

 

119.9

 

137.0

 

(12) %

 

 

(8) %

 

(4) %

Mexico

 

119.1

 

100.6

 

18 %

 

 

13 %

 

5 %

Spain

 

94.3

 

96.5

 

(2) %

 

 

— %

 

(2) %

United Kingdom

 

209.1

 

174.2

 

20 %

 

 

(4) %

 

24 %

Other developed markets

 

373.9

 

353.8

 

6 %

 

 

(3) %

 

9 %

Other emerging markets

 

604.9

 

581.1

 

4 %

 

 

(12) %

 

16 %

(a) Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

 

 

 

Three Months Ended

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

U.S.:

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

1,174

 

$

1,090

 

8 %

 

 

— %

 

8 %

Cost of Sales

 

 

228

 

 

204

 

12 %

 

 

— %

 

12 %

Gross Profit

 

 

946

 

 

886

 

7 %

 

 

— %

 

7 %

Gross Margin

 

 

80.6 %

 

 

81.3 %

 

 

 

 

 

 

 

Operating Expenses

 

 

202

 

 

206

 

(2) %

 

 

— %

 

(2) %

Other (income)/deductions-net

 

 

 

 

1

 

*

 

 

*

 

*

U.S. Earnings

 

$

744

 

$

679

 

10 %

 

 

— %

 

10 %

 

 

 

 

 

 

 

 

 

 

 

 

International:

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

956

 

$

889

 

8 %

 

 

— %

 

8 %

Cost of Sales

 

 

306

 

 

256

 

20 %

 

 

1 %

 

19 %

Gross Profit

 

 

650

 

 

633

 

3 %

 

 

(1) %

 

4 %

Gross Margin

 

 

68.0 %

 

 

71.2 %

 

 

 

 

 

 

 

Operating Expenses

 

 

156

 

 

150

 

4 %

 

 

— %

 

4 %

Other (income)/deductions-net

 

 

1

 

 

(3)

 

*

 

 

*

 

*

International Earnings

 

$

493

 

$

486

 

1 %

 

 

(3) %

 

4 %

 

 

 

 

 

 

 

 

 

 

 

 

Total Reportable Segments

 

$

1,237

 

$

1,165

 

6 %

 

 

(1) %

 

7 %

 

 

 

 

 

 

 

 

 

 

 

 

Other business activities(c)

 

 

(124)

 

 

(106)

 

17 %

 

 

 

 

 

Reconciling Items:

 

 

 

 

 

 

 

 

 

 

 

Corporate(d)

 

 

(258)

 

 

(245)

 

5 %

 

 

 

 

 

Purchase accounting adjustments(e)

 

 

(39)

 

 

(40)

 

(3) %

 

 

 

 

 

Acquisition-related costs(f)

 

 

(3)

 

 

(1)

 

*

 

 

 

 

 

Certain significant items(g)

 

 

(23)

 

 

(6)

 

*

 

 

 

 

 

Other unallocated(h)

 

 

(73)

 

 

(100)

 

(27) %

 

 

 

 

 

Total Earnings(i)

 

$

717

 

$

667

 

7 %

 

 

 

 

 

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

 

 

 

Nine Months Ended

 

 

 

 

September 30,

 

% Change

 

 

 

2023

 

 

2022

 

Total

 

 

Foreign Exchange

 

Operational(b)

U.S.:

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

3,344

 

$

3,201

 

4 %

 

 

— %

 

4 %

Cost of Sales

 

 

645

 

 

587

 

10 %

 

 

— %

 

10 %

Gross Profit

 

 

2,699

 

 

2,614

 

3 %

 

 

— %

 

3 %

Gross Margin

 

 

80.7 %

 

 

81.7 %

 

 

 

 

 

 

 

Operating Expenses

 

 

602

 

 

578

 

4 %

 

 

— %

 

4 %

Other (income)/deductions-net

 

 

 

 

(6)

 

*

 

 

*

 

*

U.S. Earnings

 

$

2,097

 

$

2,042

 

3 %

 

 

— %

 

3 %

 

 

 

 

 

 

 

 

 

 

 

 

International:

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

2,929

 

$

2,780

 

5 %

 

 

(5) %

 

10 %

Cost of Sales

 

 

912

 

 

809

 

13 %

 

 

(7) %

 

20 %

Gross Profit

 

 

2,017

 

 

1,971

 

2 %

 

 

(4) %

 

6 %

Gross Margin

 

 

68.9 %

 

 

70.9 %

 

 

 

 

 

 

 

Operating Expenses

 

 

473

 

 

456

 

4 %

 

 

(5) %

 

9 %

Other (income)/deductions-net

 

 

1

 

 

(5)

 

*

 

 

*

 

*

International Earnings

 

$

1,543

 

$

1,520

 

2 %

 

 

(2) %

 

4 %

 

 

 

 

 

 

 

 

 

 

 

 

Total Reportable Segments

 

$

3,640

 

$

3,562

 

2 %

 

 

(1) %

 

3 %

 

 

 

 

 

 

 

 

 

 

 

 

Other business activities(c)

 

 

(354)

 

 

(315)

 

12 %

 

 

 

 

 

Reconciling Items:

 

 

 

 

 

 

 

 

 

 

 

Corporate(d)

 

 

(722)

 

 

(771)

 

(6) %

 

 

 

 

 

Purchase accounting adjustments(e)

 

 

(124)

 

 

(120)

 

3 %

 

 

 

 

 

Acquisition-related costs(f)

 

 

(8)

 

 

(4)

 

*

 

 

 

 

 

Certain significant items(g)

 

 

45

 

 

(10)

 

*

 

 

 

 

 

Other unallocated(h)

 

 

(191)

 

 

(278)

 

(31) %

 

 

 

 

 

Total Earnings(i)

 

$

2,286

 

$

2,064

 

11 %

 

 

 

 

 

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational growth (a non-GAAP financial measure) is defined as growth excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition and the impact of divestiture-related gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB